Core Viewpoint - The stock of Eddiecon Holdings (09860) experienced a significant increase, closing up 9.27% at HKD 6.6, with a trading volume of HKD 41.53 million, following a report from Goldman Sachs indicating signs of recovery in the Chinese diagnostics industry starting in Q3 2025 [1] Industry Summary - Goldman Sachs' latest report suggests that the Chinese diagnostics industry, including Independent Clinical Laboratories (ICL) and In Vitro Diagnostics (IVD) companies, will show recovery signs beginning in Q3 2025 [1] - In the ICL sector, both Kingmed Diagnostics (603882) and Dian Diagnostics (300244) reported improvements in operating cash flow, with a sequential increase in revenue and an expansion in profit margins, despite not meeting revenue targets [1] - CITIC Securities noted a narrowing decline in ICL sector revenues for Q3 2025, although profits are still impacted by impairments [1] - The report highlights that companies with good cost and quality control are likely to gain market share, despite uncertainties in growth rates within the ICL industry [1] Company Summary - Eddiecon reported a gross profit of HKD 450 million and a net profit of HKD 43 million, making it the most profitable among the top three ICL companies [1] - Dian Diagnostics achieved a turnaround, reporting a net profit of HKD 10.27 million during the same period, while Kingmed Diagnostics remains in a loss position [1]